bioCSL starts delivering AFLURIA vaccine for flu season
The company intends to provide over 18 million flu vaccine doses to health facilities throughout the U.S. bioCSL has a strong reputation for reliable, timely deliveries and dedicated commercial efforts. These factors motivate customer demand for bioCSL.
An estimated two thirds of AFLURIA doses will be made accessible through single-dose, pre-filled, thimerosal-free syringes. One third of these doses will be in the form of multi-dose vials, which have the preservative thimerosal. Additionally, AFLURIA’s new, needle-free option for multi-dose vials will be made available this year.
As of today, the FDA has approved use of PharmaJet Stratis Needle-Free Injection System exclusively with the AFLURIA seasonal influenza vaccine. This allows the vaccine to be given to adults between the ages of 18 and 64.
"At bioCSL, we are focused on meeting the needs of healthcare providers for a safe and reliable vaccine supply,” Dr. Chip Altman, head of medical affairs, bioCSL Inc., said. "Seasonal influenza is a major public health concern, and we strive to deliver vaccines to providers in the United States as early as possible to give them ample time to protect their communities against the flu."